On Newsstands: WOW Spring 22

On Newsstands: WOW Spring 22

[ad_1] The new year brings new challenges, and a welcome return of some Before Times staples, which are the subjects preoccupying the WOW Singapore team in the Spring 2022 issue. While this is technically the first issue of the new year, it is really the last issue of the year that was in horology. And…

Episode #140: Spring Bucket List

Episode #140: Spring Bucket List

[ad_1] This week, we are chatting about everything on our spring bucket list (we encourage you to make one too!). We are also sharing the new ABM book club selections for spring. Plus, we answer a listener’s questions about getting older. A big thank you to our sponsors! Check out the offers from Ritual, Wondrium,…

A Night In to Yourself

A Night In to Yourself

[ad_1] A Night In to Yourself Crazy week? Us too. These are our favorite ways to unwind, from red-light masks to bath oils to something as simple as lighting a candle. If you can, start a night in with a workout or a meditation session and end it in bed with a great book. In…

Advanced physiotherapist grade in hospitals will reduce patient waiting lists – ICSP

Advanced physiotherapist grade in hospitals will reduce patient waiting lists – ICSP

[ad_1] The group has launched a competency framework for advance practice and, calling for physiotherapists to be allowed refer patients for X-ray The Irish Society of Physiotherapists (ISCP) has launched a Competency Framework for Advanced Practice Physiotherapists, calling on Government to amend the legislation to allow physiotherapists to refer for X-ray and create the Advanced…

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC

[ad_1] The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Eli Lilly and Company regarding the Biologics License Application (BLA) for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC). Sintilimab is an investigational programmed death receptor-1 (PD-1)…